Frontiers in Oncology (Jan 2020)

Genetically Determined Height and Risk of Non-hodgkin Lymphoma

  • Amy Moore,
  • Eleanor Kane,
  • Zhaoming Wang,
  • Zhaoming Wang,
  • Orestis A. Panagiotou,
  • Orestis A. Panagiotou,
  • Lauren R. Teras,
  • Alain Monnereau,
  • Alain Monnereau,
  • Alain Monnereau,
  • Nicole Wong Doo,
  • Mitchell J. Machiela,
  • Christine F. Skibola,
  • Susan L. Slager,
  • Gilles Salles,
  • Gilles Salles,
  • Gilles Salles,
  • Nicola J. Camp,
  • Paige M. Bracci,
  • Alexandra Nieters,
  • Roel C. H. Vermeulen,
  • Roel C. H. Vermeulen,
  • Joseph Vijai,
  • Karin E. Smedby,
  • Karin E. Smedby,
  • Yawei Zhang,
  • Claire M. Vajdic,
  • Wendy Cozen,
  • Wendy Cozen,
  • John J. Spinelli,
  • John J. Spinelli,
  • Henrik Hjalgrim,
  • Graham G. Giles,
  • Graham G. Giles,
  • Brian K. Link,
  • Jacqueline Clavel,
  • Jacqueline Clavel,
  • Alan A. Arslan,
  • Alan A. Arslan,
  • Alan A. Arslan,
  • Mark P. Purdue,
  • Lesley F. Tinker,
  • Demetrius Albanes,
  • Giovanni M. Ferri,
  • Thomas M. Habermann,
  • Hans-Olov Adami,
  • Hans-Olov Adami,
  • Nikolaus Becker,
  • Yolanda Benavente,
  • Yolanda Benavente,
  • Simonetta Bisanzi,
  • Paolo Boffetta,
  • Paul Brennan,
  • Angela R. Brooks-Wilson,
  • Angela R. Brooks-Wilson,
  • Federico Canzian,
  • Lucia Conde,
  • David G. Cox,
  • Karen Curtin,
  • Lenka Foretova,
  • Susan M. Gapstur,
  • Hervé Ghesquières,
  • Hervé Ghesquières,
  • Martha Glenn,
  • Bengt Glimelius,
  • Rebecca D. Jackson,
  • Qing Lan,
  • Mark Liebow,
  • Marc Maynadie,
  • James McKay,
  • Mads Melbye,
  • Mads Melbye,
  • Lucia Miligi,
  • Roger L. Milne,
  • Roger L. Milne,
  • Thierry J. Molina,
  • Lindsay M. Morton,
  • Kari E. North,
  • Kari E. North,
  • Kenneth Offit,
  • Marina Padoan,
  • Alpa V. Patel,
  • Sara Piro,
  • Vignesh Ravichandran,
  • Elio Riboli,
  • Silvia de Sanjose,
  • Silvia de Sanjose,
  • Richard K. Severson,
  • Melissa C. Southey,
  • Anthony Staines,
  • Carolyn Stewart,
  • Ruth C. Travis,
  • Elisabete Weiderpass,
  • Stephanie Weinstein,
  • Tongzhang Zheng,
  • Stephen J. Chanock,
  • Nilanjan Chatterjee,
  • Nilanjan Chatterjee,
  • Nilanjan Chatterjee,
  • Nathaniel Rothman,
  • Brenda M. Birmann,
  • James R. Cerhan,
  • Sonja I. Berndt

DOI
https://doi.org/10.3389/fonc.2019.01539
Journal volume & issue
Vol. 9

Abstract

Read online

Although the evidence is not consistent, epidemiologic studies have suggested that taller adult height may be associated with an increased risk of some non-Hodgkin lymphoma (NHL) subtypes. Height is largely determined by genetic factors, but how these genetic factors may contribute to NHL risk is unknown. We investigated the relationship between genetic determinants of height and NHL risk using data from eight genome-wide association studies (GWAS) comprising 10,629 NHL cases, including 3,857 diffuse large B-cell lymphoma (DLBCL), 2,847 follicular lymphoma (FL), 3,100 chronic lymphocytic leukemia (CLL), and 825 marginal zone lymphoma (MZL) cases, and 9,505 controls of European ancestry. We evaluated genetically predicted height by constructing polygenic risk scores using 833 height-associated SNPs. We used logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CI) for association between genetically determined height and the risk of four NHL subtypes in each GWAS and then used fixed-effect meta-analysis to combine subtype results across studies. We found suggestive evidence between taller genetically determined height and increased CLL risk (OR = 1.08, 95% CI = 1.00–1.17, p = 0.049), which was slightly stronger among women (OR = 1.15, 95% CI: 1.01–1.31, p = 0.036). No significant associations were observed with DLBCL, FL, or MZL. Our findings suggest that there may be some shared genetic factors between CLL and height, but other endogenous or environmental factors may underlie reported epidemiologic height associations with other subtypes.

Keywords